These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36917199)

  • 1. Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond.
    Peffault de Latour R; Risitano AM
    Am J Hematol; 2023 May; 98 Suppl 4():S3-S4. PubMed ID: 36917199
    [No Abstract]   [Full Text] [Related]  

  • 2. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.
    Hill A; Ridley SH; Esser D; Oldroyd RG; Cullen MJ; Kareclas P; Gallagher S; Smith GP; Richards SJ; White J; Smith RA; Hillmen P
    Blood; 2006 Mar; 107(5):2131-7. PubMed ID: 16322479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
    Risitano AM
    Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
    Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
    Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
    Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
    Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
    Risitano AM; Frieri C; Urciuoli E; Marano L
    Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of various therapies on complement-sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria.
    Shichishima T; Saitoh Y; Noji H; Terasawa T; Maruyama Y
    Int J Hematol; 1996 Jun; 63(4):291-302. PubMed ID: 8762812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cryptantigen Th on paroxysmal nocturnal hemoglobinuria erythrocytes in association with a hemolytic exacerbation.
    Nakakuma H; Hidaka M; Nagakura S; Nishimura Y; Iwamoto N; Horikawa K; Kawaguchi T; Kagimoto T; Takatsuki K
    J Clin Invest; 1995 Jul; 96(1):201-6. PubMed ID: 7542278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
    Parker CJ; Stone OL; Bernshaw NJ
    J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-red cell interactions at low ionic strength: erythrocyte complement coating and hemolysis of paroxysmal nocturnal hemoglobinuria cells.
    Jenkins DE; Hartmann RC; Kerns AL
    J Clin Invest; 1967 May; 46(5):753-61. PubMed ID: 6025481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
    Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
    Front Immunol; 2020; 11():1460. PubMed ID: 32793201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
    Lee M; Narayanan S; McGeer EG; McGeer PL
    PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.